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Androgen-independent prostate cancer shows limited response to existing systemic therapies. Recent advances in prostate-selective 
targeting of small molecule inhibitors and bacterial toxins have created opportunities to design a new generation of therapies for 
advanced prostate cancer. Yet prioritizing targets for these therapies remain challenging, since multiple mechanisms contribute 
to the pathophysiology of androgen-independent prostate cancer. This review explores the possibility of targeting the apoptosis 
regulatory network as most direct approach to efficient treatment of advanced androgen-independent prostate cancer.
Key Words: prostate cancer, apoptosis, prostate-selective therapies, PSA-activated pro-drugs, PSMA-targeting toxins.
REDUNDANT MECHANISMS 
OF ANDROGEN INDEPENDENCE 
IN ADVANCED PROSTATE CANCER POSE 
CHALLENGE FOR CURRENT THERAPIES
Androgen ablation remains the most effective sys-
temic therapy for advanced prostate cancer, that de-
lays cancer progression 90% of cases. Still, the dise-
ase invariably recurs as androgen-independent 
cancer, for which no curative treatment is available. 
A critical role of the androgen signaling axis in pros-
tate cancer has been unequivocally demonstrated, 
as androgen independence has been connected 
with activation of the androgen receptor (AR) despite 
androgen ablation the rapy. Mutations in AR that lead 
to hypersensitivity to low concentrations of androgen, 
or ligand-independent activation of AR have been 
identified [1]. New therapies, including abiraterone 
acetate (an inhibitor of androgen biosynthesis), and 
MDV3100 (an AR antagonist that prevents nuclear 
translocation and chromatin binding) can achieve 
“complete androgen blockade”. Still, even with com-
plete inhibition of AR signalling, prostate cancer will 
eventually progress [2–4].
Broader analysis of androgen independence that 
extends beyond the AR axis connected the signaling 
pathways from EGFR (HER) family, GPCRs, non-
receptor tyrosine kinases of the Src family, PI3K, 
NF-kB, myc, and other regulatory molecules with 
advanced androgen-independent prostate cancer [5, 
6]. Of these, the PI3K pathway emerged as most 
prominent, since mutations leading to its activation 
of PI3K pathway were almost invariably detected 
by whole-genome sequencing of advanced prostate 
cancer [7, 8]. Yet unlike inhibitors of AR signaling that 
extend survival of patients with advanced metastatic 
prostate cancer up to 16–18 months, inhibitors of other 
signaling pathways, including PI3K/mTOR inhibitors 
and inhibitors of receptor tyrosine kinases, did not 
show significant survival benefit [9–11].
This modest anticancer efficacy is not unique 
to prostate cancer. Over the last 20 years, nume-
rous inhibitors of signal transduction enzymes have 
been developed. These inhibitors proved invaluable 
as experimental tools, yet with the notable exception 
of Gleevec, most failed to meet high expectations 
to substantially increase patient survival [12]. Several 
reasons may account for inefficiency of signal trans-
duction inhibitors in prostate cancer.
First, although complete androgen blockade af-
fects other tissues and has a range of metabolic and 
behavioral side effects, prostate cells are the most sen-
sitive to androgen ablation and die first [6]. In contrast, 
AR-independent signaling pathways play important 
roles in normal physiology of cells and tissues outside 
of prostate glands. Therefore, complete inhibition 
of these pathways is likely to induce morbid side effects 
that limit doses of inhibitors and do not allow complete 
inhibition of the signaling pathway in prostate tumors.
Second, there is significant variability between 
individual tumors and patients in signaling pathways 
that contribute to androgen independence. As a result, 
few patients will show the expected response to inhibi-
tors of a specific pathway. When results of all treated 
patients are combined in a clinical trial, the differences 
between experimental and control groups may still did 
not show a statistically significant difference despite 
few responsive patients.
Third, analyses of topologies of signal transduction 
networks show a substantial level of redundancy, es-
pecially at the “top” at the receptor level [13, 14]. Thus, 
even complete inhibition of apical protein kinase or other 
signaling molecules will leave alternative pathways intact 
and will have little effect on critical effector molecules that 
determine the extent of phenotypic response. It appears 
that to accomplish an effective anti-tumor response, 
several signaling pathways must be inhibited.
Androgen ablation triggers apoptosis in differenti-
ated prostate epithelial cells, yet in advanced andro-
gen-independent prostate tumors, cells no longer die 
upon androgen deprivation. In androgen-independent 
prostate cancer, the default response of prostate cells 
to androgen ablation (i.e. apoptosis) is diverted by other 
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signaling pathways. Following this logic, targeting 
anti-apoptotic signals should complement androgen 
ablation therapy. Because apoptosis is most common 
evolutionary refined mechanism of elimination of cancer 
cells by intrinsic organismal responses and anti-cancer 
therapies [15], treatment modalities that aim at apop-
tosis induction are likely to be most efficient.
BAD AND MCL-1 ARE KEY NODES 
OF APOPTOSIS REGULATORY NETWORK
What is known about apoptosis regulation in prostate 
cancer cells, and how it could be induced most efficient-
ly in prostate tumors? Seminal experiments by Charles 
Huggins that showed involution of prostate glands after 
androgen ablation in beagles were reproduced in other 
animal models with similar results [16]. In 1988, a group 
led by John Isaacs reported increased apoptosis in re-
sponse to androgen ablation in rats [17]. Apoptosis 
in the prostate gland after androgen ablation therapy 
has been confirmed by others, yet the precise mecha-
nism of apoptosis induction remained unknown [18, 
19]. As the mechanism of apoptosis regulation became 
better understood, the critical role of Bcl2 protein fa-
mily in mitochondrial outer membrane permeability and 
commitment to apoptosis was established. Transgenic 
mice with increased expression of Bcl2 showed delayed 
prostate involution after androgen ablation, suggesting 
that common principles of apoptosis regulation were 
also true for prostate glands. Still, no convincing data 
on changes in Bcl2 family proteins (or other apoptosis-
regulatory molecules) in prostate glands after androgen 
ablation were reported [20].
Most studies on the mechanisms of apoptosis 
regulation used tissue culture models of cells derived 
from prostate tumors: LNCaP, PC3, and DU145 [21]. 
Of these cell lines, only LNCaP cells remain androgen-
responsive, although they are no longer depend on an-
drogen for survival [22]. Apoptosis regulation in LNCaP 
cells was triggered by the loss of PTEN phosphatase, 
which negatively regulates the PI3K pathway [23, 
24]. As a result, PI3K signaling is constitutively active 
and protects LNCaP cells from apoptosis, whereas 
inhibition of the PI3K pathway induces apoptosis 
in these cells. Extensive analysis of apoptosis regula-
tion in LNCaP and in C42 cells (derived from LNCaP 
cells by passaging in immunodeficient mice) identi-
fied several signal transduction pathways that inhibit 
apoptosis [13, 25].
These pathways activated by EGFR and GPCR 
agonists phosphorylate BAD and protect cells from 
apoptosis induced by PI3K inhibitors that triggered 
dephosphorylation of BAD. BAD knockout rendered 
LNCaP and C42 cells insensitive to apoptosis induction 
by PI3K inhibitors and, conversely, expression of BAD 
with mutated phosphorylation sites disabled anti-
apoptotic signaling by EGFR, GPCRs, and constitutive-
ly active PI3K [13, 26]. Thus, BAD phosphorylation was 
established as a convergence point for anti-apoptotic 
signaling pathways in prostate cancer cells. However, 
the principal role of BAD was questioned when dyna-
mics of apoptosis induction and BAD dephosphoryla-
tion were compared. In cells treated with PI3K inhibi-
tors, BAD was dephosphorylated within 3–4 hours, but 
apoptosis was not detected until 12 hours. In contrast, 
the combination of a PI3K inhibitor and a protein 
synthesis inhibitor induced apoptosis in 6 hours, yet 
dynamics of BAD dephosphorylation in cells treated 
with PI3K alone or with a combination of a PI3K inhibitor 
and a protein synthesis inhibitor were similar, despite 
dramatic differences in timing of apoptosis induc-
tion [27]. These observations prompted the search 
for another regulatory molecule that commits prostate 
cancer cells to undergo apoptosis.
Earlier reports on interaction preferences between 
members of Bcl2 family identified BclXL, Bclw and 
Bcl2 as binding partners of BAD, whereas another anti-
apoptotic protein Mcl-1 does not bind BAD [28]. Thus, 
in a dephosphorylated state, BAD will bind and neutral-
ize anti-apoptotic effects of BclXL, Bclw, and Bcl2, but 
not of Mcl-1. Consequently, in cells that express Mcl-1, 
BAD dephosphorylation will have only a mild pro-
apoptotic effect. Mcl-1 is indeed expressed in LNCaP 
cells, and treatment with PI3K inhibitors pre dictably 
induces only delayed apoptosis, since expression 
of Mcl-1 is not affected. In contrast, the combination 
of a PI3K inhibitors and a protein synthesis inhibitor 
decreased both BAD phosphorylation and Mcl-1 ex-
pression and induced rapid apoptosis [27]. Experi-
ments with shRNA-mediated knockdown of Mcl-1 and 
expression of phosphorylation-deficient mutants 
of BAD confirmed the essential role of simultaneous 
BAD dephosphorylation and Mcl-1 loss in inducing 
rapid apoptosis [27].
Mcl-1 is characterized by rapid turnover, with over 
80% of protein degraded within 3 hours after protein 
synthesis is inhibited. Rapid turnover of Mcl-1 is dic-
tated by ubiquitination-mediated targeting to protea-
somes. Ubiquitination in turn is regulated by phospho-
rylation, which — depending on the specific site — may 
either stimulate or inhibit Mcl-1 ubiquitination [29, 30].
Several signaling mechanisms can induce tran-
scription and/or delay Mcl-1 phosphorylation 
and increase overall expression of Mcl-1 protein. 
The transcriptional factors STAT, CREB, HIF-1, and 
TCF, as well as micro-RNA, were implicated in incre-
ased synthesis of Mcl-1 protein. On the other hand, 
phosphorylation by the ERK pathway at Thr92 and 
Thr163 prolongs Mcl-1 half-life, whereas phosphory-
lation at S169 by GSK3b accelerates degradation. 
Thus, signaling pathways emanating from Ras/MAPK, 
PI3K/Akt/Gsk3b, GPCR/PKA/CREB and RTK/STAT 
could upregulate Mcl-1 expression [30, 31]. Analysis 
of BAD phosphorylation identified PKA, RAS/MAPK, 
Rac/PAK and PI3K/Akt pathways as responsible for 
anti-apoptotic effects of GPCR and EGFR agonists and 
loss of PTEN in prostate cells [13, 25, 26]. In summary, 
levels of Mcl-1 expression and BAD phosphorylation 
are dynamically regulated by overlapping signal trans-
duction pathways, most of which could be inhibited 
with existing drugs.
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The decisive roles of BAD dephosphorylation 
and Mcl-1 loss depend on the expression pattern 
of other members of the Bcl2 family. For example, 
the PC3 prostate cancer cell line, with high expression 
of BclXL, shows less apoptosis when BAD dephos-
phorylation and loss of Mcl-1 is induced. Likewise, less 
apoptosis is observed in DU145 cells with diminished 
expression of BAX. However, when BclXL expression 
in diminished and BAX expression is restored, both 
cells lines show comparable apoptosis compared 
to LNCaP cells. Taken together, these results identify 
BAD and Mcl-1 as critical nodes of apoptosis regula-
tory networks, yet their impact on apoptosis depends 
on the status of other network members [27].
To translate this information into improved therapies 
for advanced prostate cancer, several issues must 
be addressed. 1) A systems approach to the analysis 
of Bcl2 family proteins is needed, to identify prostate 
tumors that may respond to BAD dephosphorylation 
and Mcl-1 loss. 2) Signaling pathways that control BAD 
phosphorylation and synthesis of Mcl-1 play important 
physiological roles in other tissues, and inhibiting these 
pathways is likely to induce prohibiting side effects. 
A possible way to minimize these side effects is to use 
prostate-selective inhibitors. As advanced prostate can-
cer affects mostly older men, preservation of a functional 
prostate gland is seldom a priority for these patients [32].
PROSTATE-SELECTIVE THERAPIES 
THAT TARGET BAD PHOSPHORYLATION 
AND MCL-1
Designers of prostate-selective drugs have uti-
lized two approaches: making a pro-drug activated 
by prostate-specific antigen (PSA) cleavage, or linking 
active toxins to prostate-specific membrane antigen 
(PSMA)-targeting antibodies.
The approach using PSA-activated pro-drugs 
pioneered by John Isaacs’ group at Johns Hopkins 
University by linking a PSA substrate peptide to thapsi-
gargin, an inhibitor of the Ca2+ channel pump in the en-
doplasmic reticulum. Apoptosis was induced in pros-
tate cancer cell upon 24 h exposure. This approach 
was expanded by this group and others by generating 
PSA-activated pro-drugs of doxorubicin, vinblastine, 
thapsigargin, paclitaxel and proaerolysin [33–38].
However, no pro-drug inhibitors of protein kinases 
that can be activated by PSA cleavage and inhibit their 
targets only in prostate cells have been made. Since 
PI3K is the most frequently activated signaling pathway 
in advanced prostate cancer, and our earlier publica-
tions identified PI3K as the major signaling pathway 
responsible for constitutive BAD phosphorylation 
in prostate cancer cells, it was reasonable to test 
whether a PI3K inhibitor pro-drug could be created. 
As we have shown recently, LY294002, a widely used 
PI3K inhibitor, can be converted into inactive pro-drug 
that selectively inhibits PI3K in prostate cancer cell 
lines (C42 and LNCaP) cells that secrete PSA, but not 
in breast cancer cells, which do not secrete PSA [39]. 
Future experiments will tell whether more potent in-
hibitors that block PI3K activity at nM concentration 
can be generated, and whether these pro-drug PI3K 
inhibitors can selectively block PI3K activity in pros-
tate tumors in vivo [40]. Should these experiments 
succeed, it will open the door for design of prostate-
selective inhibitors of protein kinases like EGFR, MEK, 
PAK or PKA that were identified as upstream kinases 
of BAD in prostate cancer cells.
A different approach to producing prostate-tar-
geted drugs is based on fusing toxins to antibodies 
against PSMA. The most attention has been generated 
by J591 monoclonal antibodies developed by Neil 
Bander, now used for both therapeutic and diagnostic 
applications [41]. Another set of monoclonal antibo-
dies has been raised by a German group that fused 
variable light chain of these antibodies with Pseudo-
monas Exotoxin A [42], which ribosylates elongation 
factor 2 and inhibits the translation step of protein 
synthesis. A recent analysis of synergistic apoptosis 
induction in prostate cancer cells by PI3K and pro-
tein synthesis inhibitors identified Mcl-1 as a critical 
regulatory protein responsible for pro-apoptotic ef-
fects of protein synthesis inhibitors in prostate cancer 
cells [27, 43].
In summary, both BAD phosphorylation and 
Mcl-1 expression are controlled by several convergent 
signal transduction pathways [30, 31, 44, 45]. When 
Mcl-1 expression is decreased simultaneously with 
BAD dephosphorylation (triggered by PI3K inhibition), 
robust apoptosis in prostate cancer cells is induced 
within 3–4 hours. In contrast, when either BAD phos-
phorylation or Mcl-1 expression alone was inhibited, 
apoptosis was evident only after 12–24 hours [27]. 
Thus, monitoring BAD phosphorylation and Mcl-1 ex-
pression along with immediate targets of signaling in-
hibitors allows prediction of whether prostate-selective 
inhibitors will have intended effects. In contrast, moni-
toring only inhibition of immediate targets will have 
less predictive power because of multiple redundant 
signals that converge on Mcl-1 and BAD.
Analysis of protein expression and phosphorylation 
is relatively straightforward for hematopoietic cancers, 
yet for solid tumors it poses a substantial challenge. 
Repeated biopsies are needed, which is especially 
problematic for metastatic tumors. To circumvent the 
need for tumor biopsies, surrogate markers have been 
proposed. For example, analysis of EGFR phosphory-
lation in hair follicles has been used to monitor efficacy 
of EGFR kinase inhibitors [46]. However, this approach 
may not be applied for monitoring BAD and Mcl-1, 
since signaling pathways that regulate these proteins 
are likely different in prostate than in other tissues. Fur-
thermore, considering the high level of hete rogeneity 
observed within prostate tumors, several biopsies 
may be required to confirm that Mcl-1 expression and 
BAD phosphorylation throughout the tumor tissue are 
changing. Recently, circulating tumor cells attracted 
significant attention as a possible replacement for 
tumor biopsies. But it remains unproven whether, 
taken out of the microenvironment, tumor cells can 
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adequately represent signaling events inside solid 
tumors [47]. One possible alternative is using pri-
mary xenografts of tumor biopsies to select optimal 
combination of therapies without subjecting cancer 
patients to highly invasive procedures [48]. In fact, 
a panel of primary xenografts established from tumor 
biopsies could be used to test whether monitoring BAD 
phosphorylation and Mcl-1 expression better predicts 
a curative response than monitoring immediate targets 
of signal transduction inhibitors.
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